{"brief_title": "AZD5438 in Patients With Advanced Solid Malignancies", "brief_summary": "Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction with preclinical and the available clinical pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the development of AZD5438 as a potential anti-cancer agent would be discontinued.", "condition": ["Neoplasms"], "intervention_type": ["Drug"], "intervention_name": ["AZD5438"], "criteria": "Inclusion Criteria: - Advanced solid malignancy - Cancer refractory to standard treatments or for which no standard therapy exits Exclusion Criteria: - Radiotherapy within 3 weeks of the start of treatment - Investigational product within the last 3 weeks - Systemic cytotoxic anti-cancer therapy within the last 3 weeks - Any significant clinical disorder that makes it undesirable for the patient to participate", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "advanced, solid, malignancies", "id": "NCT00088790"}